Europital announces the official launching and certification attainment of its latest product.
Europital announces the official launching and certification attainment of its latest product. From January 2015 “Penthu®: The Future of Medical Management in Clinical Trials” will be available in the market.
Penthu® is an innovative and intuitive platform that drives performance, knowledge and efficiencies in clinical trials. This electronic tool allows project team to provide timely medical guidance and effficiently manage medical issues across multiple projects with minimal effort from the user’s side, thus reducing time, energy and resources while maximizing quality, knowledge and transparency.
This communication and knowledge trasnfer platform has been developed by clinical research professional and founded in three-core principles:
Thanks to an interactive environment that provides the kind of transparency needed to share and access information, the team’s performance is increased, creating real partnerships between project members.
Recently, PenThu® became an officially registered trademark in Europe. The European OHIM issued last November 2014 the Certificate of Registration for PenThu® as a Registered Trademark in the 28 member states of the European Union.
For more information about PenThu, visit www.pethu.com
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.